Review Article

The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment

Takamitsu Sasaki,1 Kuniyasu Hiroki,2 and Yuichi Yamashita1

1 Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka 814-0180, Japan
2 Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan

Correspondence should be addressed to Takamitsu Sasaki; takamitu@fc4.so-net.ne.jp

Received 3 May 2013; Accepted 25 June 2013

Academic Editor: Davide Vigetti

Copyright © 2013 Takamitsu Sasaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Despite significant improvements in diagnosis, surgical techniques, and advancements in general patient care, the majority of deaths from cancer are caused by the metastases. There is an urgent need for an improved understanding of the cellular and molecular factors that promote cancer metastasis. The process of cancer metastasis depends on multiple interactions between cancer cells and host cells. Studies investigating the TGFα-EGFR signaling pathways that promote the growth and spread of cancer cells. Moreover, the signaling activates not only tumor cells, but also tumor-associated endothelial cells. TGFα-EGFR signaling in colon cancer cells creates a microenvironment that is conducive for metastasis, providing a rationale for efforts to inhibit EGFR signaling in TGFα-positive cancers. In this review, we describe the recent advances in our understanding of the molecular basis of cancer metastasis.

1. Introduction

Epidermal growth factor receptor (EGFR) is a key factor in epithelial malignancies, and its activity enhances tumor growth, invasion, and metastasis [1]. EGFR is a member of the ErbB family of tyrosine kinase receptors that transmit a growth-inducing signal to cells that have been stimulated by an EGFR ligand (e.g., TGFα and EGF) [2, 3]. In normal tissues, the availability of EGFR ligands is tightly regulated to ensure that the kinetics of cell proliferation precisely match the tissues’ requirements for homeostasis. In cancer, however, EGFR is often perpetually stimulated because of the sustained production of EGFR ligands in the tumor microenvironment [4, 5] or as a result of a mutation in EGFR itself that locks the receptor in a state of continual activation [6]. Aberrant expression of TGFα or EGFR by tumors typically confers a more aggressive phenotype and is thus often predictive of poor prognosis [7–10]. Not surprisingly, EGFR has emerged as a principal target for therapeutic intervention.

2. EGF-Like Ligands and EGFR

Receptor tyrosine kinases (RTKs) are primary mediators of many of these signals and thus determine the fate of the cell: growth, differentiation, migration, or death. The ErbB family of RTKs consists of four receptors: ErbB-1 (EGFR), ErbB-2 (HER2 or Neu), ErbB-3, and ErbB-4 [11, 12]. The mature EGFR receptor is composed of a single polypeptide chain of 1186 amino acid residues and a substantial amount of N-linked oligosaccharide. A single hydrophobic membrane anchor sequence separates an extracellular ligand-binding domain from a cytoplasmic domain that encodes an EGF-regulated tyrosine kinase. A single hydrophobic membrane anchor sequence separates an extracellular ligand-binding domain from a cytoplasmic domain that encodes an EGF-regulated tyrosine kinase [13–15]. The hallmark of the cytoplasmic protein of this receptor is the sequence defining the tyrosine kinase domain.

Ligand binding induces receptor hemo- or heterodimerization that is essential for activation of the tyrosine kinase. Six mammalian ligands that bind to EGFR have been characterized, including epidermal growth factor (EGF), transforming growth factor-α (TGFα), amphiregulin,
heparin-binding EGF-like growth factor, betacellulin, and epiregulin [16, 17]. Tyrosine kinase activity following ligand binding is essential and is the first step in the EGF signal transduction pathway [18], once the ligand binds the receptor and further stimulates multiple signal pathways including Ras/mitogen-activated protein kinase, phosphatidylinositol 3-kinase/Akt, nuclear factor-κB, and others [19–22].

3. Colorectal Cancer and TGFα/EGFR Signaling

Studies investigating the signaling pathways that promote the growth and spread of cancer cells suggest that the information transmitted by means of TGFα-EGFR signaling is particularly important for progression of tumors that develop in the colon [23–26].

Overexpression of the EGFR and its ligands, TGFα, has been correlated with poor prognosis [27–29]. Colon cancer cells secrete TGFα in response to hypoxia and the ligand signals, the cell surface EGFR, to initiate a sequence of cell survival programs [30]. This activation of the EGFR signaling pathways stimulates downstream signaling cascades involved in cell proliferation (Ras/mitogen-activated protein kinase [MAPK]) and antiapoptosis (phosphatidylinositol 3-kinase [PI3K]/Akt) [20, 31, 32]. In addition, the overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis [27, 32, 33].

4. Metastatic Colorectal Cancer

The expression levels of TGFα, EGF, and EGFR have been shown to correlate with progressive growth, development of metastasis, and resistance to chemotherapy [27, 32, 34]. Measurements of EGFR expressed on human colon cancer cells in vitro indicate that metastatic cells may express as much as five-times more EGFR in comparison to non-metastatic cells [35]. Reports examining the distribution of EGFR and TGFα on colorectal biopsies also conclude that the receptor-ligand pair is a characteristic feature of more advanced tumors [27, 36–38].

5. Microenvironment of Colon Cancer for Metastasis

The concern of the microenvironment of tumors has been growing. The process of cancer metastasis is sequential and selective and contains stochastic elements. The growth of metastases represents the endpoint of many lethal events that few tumor cells can survive. Angiogenesis refers to the development of new blood vessels from the preexisting vasculature. Angiogenesis plays a key role in the initiation of metastases. Tumor cell proliferation and survival depend on the vasculature to supply adequate oxygen and nutrients [39]. The extent of angiogenesis depends on the balance between proangiogenic and antiangiogenic factors released by tumor cells and host cells [40, 41]. The communication networks that are established between tumor cells and the nonneoplastic cells in the microenvironment of primary tumors play a critical role in tumor growth and development of metastasis [42, 43].

Data derived from examinations of human lung cancer brain metastases indicate that tumor cell division takes place within 75 μm of the nearest blood vessel, whereas tumor cells residing beyond 150 μm from a vessel undergo programmed cell death [44]. The turnover rate of endothelial cells within the tumor-associated vessels is 20 to 2,000 times faster than the rates of the vessels in normal organs [45]. One recent detailed study of the multiple clinical specimen of human neoplasms reported that proliferation rate of endothelial cells within the vasculature of normal human organs has been reported to be <0.01%, whereas 2% to 9% of endothelial cells in tumor-associated vessels divide daily [46].

Expression of EGF, VEGF, or their respective receptors has been shown to correlate with angiogenesis and progressive growth of human carcinomas of the colon [47]. Furthermore, the expression of EGFR, VEGFR, and the phosphorylated receptors was observed on tumor-associated endothelial cells. These receptor and phosphorylated receptor were expressed on tumor-associated endothelial cells only when the tumor cells expressed the relevant ligands. These findings suggest that ligands released by tumor cells can upregulate the expression of receptors on tumor-associated endothelial cells in a paracrine manner [48–50] (Figure 1).

The angiogenic proteins, VEGFA and IL-8, were strongly expressed in the microenvironment of tumors that produced TGFα. In contrast, expression levels of VEGFA and IL-8 were considered unremarkable in TGFα-deficient tumors. VEGFA is often regarded as the prototypical angiogenic protein in that it can stimulate each of the cellular responses required for the generation of a new vascular bed (e.g., migration, proliferation, protease production, and cell survival) [51, 52]. There are also several lines of evidence suggesting that some cells rely on TGFα-induced stimulation of EGFR to enhance their production of IL-8. These data demonstrate that the extensive VEGF network (autocrine and paracrine) generated by TGFα-expressing colon cancer cells leads to a greater production of proangiogenic proteins (TGFα, VEGFA, and IL-8) in the microenvironment of primary tumors (Figure 2).

Several other factors that promote angiogenesis and tumor cell invasion were also preferentially expressed in the microenvironment of TGFα-positive tumors. Specifically, we noted robust expression of two members of the MMP family, MMP-2 and MMP-9, in tumors that were positive for TGFα [50] (Figure 2). These proteolytic enzymes perform several key functions during angiogenesis (e.g., increase the bioavailability of angiogenic proteins, degrade basement membrane barriers, and promote endothelial cell migration) and metastasis (e.g., invasion and extravasation) [53].

Macrophages are also capable of creating structural and biochemical imbalances in the extracellular matrix. A closer inspection of the tumor-infiltrating macrophages in TGFα-positive tumors showed that these cells express the lymphangiogenic growth factor VEGFC. The few macrophages
present in the TGF\(\alpha\)-negative tumors in our study did not express VEGFC, but they did so when tumor cells were transfected with TGF\(\alpha\) transgenes and then implanted into the cecal walls of mice [50] (Figure 3). These results add to the growing evidence that suggests that macrophages are a major source of VEGFC in pathological tissues and, therefore, function as central regulators of the lymphatic vascular surface area [54, 55].

The number of tumor-associated lymphatic vessels in the different tumors was determined by counting the number of vessels that were positive for LYVE-1. LYVE-1 is an integral membrane protein that functions as the receptor for the glycosaminoglycan hyaluronan. LYVE-1 is also expressed by sinusoidal endothelial cells in the liver and spleen and by some macrophages [32]. We found that the number of lymphatic vessels in EGFR-expressing tumors was fourfold higher than that observed in EGFR-deficient tumors, demonstrating that TGF\(\alpha\)-EGFR signaling is an important cofactor for expansion of the tumor-associated lymphatic vascular network [56] (Figure 4).

Supportive evidence for the involvement of TGF\(\alpha\) in metastasis comes from a recent study that identified TGF\(\alpha\) as a member of the gene set that identifies colorectal cancer cells that metastasize to the liver [57]. Alternatively, it has been known for some time now that a high vascular density increases the likelihood that tumor cells will enter the systemic circulation and reach distal organs of metastasis [58], and we found that the activation of autocrine and paracrine TGF\(\alpha\)/EGFR signaling networks affects the tumor microenvironment in colon cancer and determines its impact on the formation of metastases.

6. Microenvironment of Biliary Tract Cancers for Metastasis

Biliary tract cancers express EGFR in 60.7% of cases [59]. The EGFR-overexpressing gallbladder cancer (GBC) cases show poorly differentiated histology and decreased survival of 1.5 years in median survival [60]. Amplification and point mutations of the EGFR gene have been reported to be 1% and 15%–26.5%, respectively, in GBC [61–63]. The HGF receptor c-Met is involved in the early carcinogenesis of biliary tract cancers [64]. c-Met is expressed in 74% of invasive GBC and is associated with invasive depth [65]. Because HGF is secreted from fibroblasts, c-Met activation depends on the cancer-host interaction [66]. Transforming growth factor-b is widely expressed in advanced GBC and is associated with angiogenesis and tumor-associated macrophage infiltration as well as with stromal fibrosis [67, 68]. Epidermal growth factor receptor, c-Met, and TGF-b have recently been implicated in the process of epithelial-mesenchymal transition (EMT) [69–71]. EMT comprises a switch in cell differentiation from polarized epithelial cells to contractile and motile mesenchymal cells [72]. In EMT-type cells, the reduction of the epithelial marker E-cadherin (ECD) occurs in parallel with the induction of the mesenchymal marker...
Figure 2: Immunohistochemical analyses of expression of VEGFA, IL-8, MMP-2, and MMP-9 in orthotopically implanted colon tumors. The parental colon cancer cell line originates from a primary human colon carcinoma. The clones were expanded, and the resulting populations were screened for production of TGFα. The microenvironment of selected high level TGFα tumors is enriched in VEGFA, IL-8, MMP-2, and MMP-9. Expression of the angiogenic proteins in tumors that do not express TGFα is significantly attenuated. Scale bars = 100 μm [50].
Figure 3: Immunofluorescent staining of LYVE-1, F4/80, and VEGFC in human colon carcinoma cells expressing different levels of TGFα. Lymphatic vessels are labeled with LYVE-1 (green) and macrophage cells with F4/80 (red). The number of tumor-associated lymphatic vessels was greatest in selected high-level TGFα tumors and fewest in tumors that do not express TGFα. Tumor recruitment of macrophages was also fewest in tumors that do not express TGFα. Macrophage cells localized to selected high level TGFα tumors also expressed LYVE-1. The macrophage population recruited to TGFα-expressing tumors also produced abundant levels of the lymphatic endothelial cell growth factor VEGFC. Scale bars = 100 μm [50].

Figure 4: Mean density of LYVE-1 on orthotopic colon tumors expressing different levels of EGFR. The SW620CE2 is human colon cancer cell line. SW620 cells were injected into the cecal wall of nude mice. Three months after the injection, cecal tumors were harvested. Cells were established in culture. Primary cultures were passaged in vitro two or three times, and then, cells were injected into the cecum of another set of nude mice. The selection cycle was repeated two times to yield cell lines designated SW620CE2. SW620CE2 did not produce detectable levels of EGFR. SW620CE2/EGFR was established from SW620CE2 which was transfected sense EGFR plasmids. Cells (5 × 10⁶) in 50 μL of Hanks’ buffered saline solution were injected into the cecal wall of nude mice. The number of lymphatic vessels in SW620CE2/EGFR tumors was fourfold higher than that observed in SW620CE2 tumors [56].
vimentin (VIM) [73]. EMT occurs during cancer progression and enhances invasion and metastasis [72].

7. Strategy of Treatment

Inhibiting signaling pathways through EGFR represents a good strategy for therapeutic intervention. Gefitinib inhibits EGF-stimulated EGFR autophosphorylation in a broad range of EGFR-expressing human cancer cell lines [74]. Cetuximab, a monoclonal antibody targeting EGFR, has been shown to induce apoptosis of colorectal cancer cells [75–77]. TGFα-EGFR signaling in both tumor-associated endothelial cells and the tumor cells themselves is important in the progression of colon cancer. Abrogating the signaling activation by a dual tyrosine kinase inhibitor in combination with conventional therapy can induce a significant decrease in proliferation of tumor cells and significant apoptosis of both tumor cells and endothelial cells. Targeting the EGFR and VEGF signaling in tumor vasculature with antineovascular therapy provides a new approach to the treatment of colon cancer.

In cholangiocellular carcinoma cell lines, the anti-EGFR antibody cetuximab is partially effective in EGFR-expressing cells [78]. KRAS mutations affect the efficacy of cetuximab in these cells. Gefitinib, a selective EGFR tyrosine kinase inhibitor, inhibits the phosphorylation of EGFR, ERK, and AKT and induces G1 arrest and apoptosis by upregulating p21 and p27 and BAX activation in GBC cells [79]. Epidermal growth factor receptor targeting is, therefore, critical in the treatment of GBC.

8. Conclusion

The activation of TGFα-EGFR signaling in primary colon tumors contributes to the spread of tumor cells to lymph nodes and the liver. TGFα-expressing tumors are more proficient in their ability to initiate metastases by virtue of their ability to communicate with the resident nontumor cell population. Therapeutic interventions that are designed to block EGFR signaling in TGFα-positive colon tumors will likely have a negative impact on a number of processes that are essential for metastasis formation.

Abbreviations

EGF: Epidermal growth factor  
EGFR: Epidermal growth factor receptor  
TGFα: Transforming growth factor-α  
RTKs: Receptor tyrosine kinases  
VEGF: Vascular endothelial growth factor  
VEGFR: Vascular endothelial growth factor receptor  
IL-8: Interleukin-8  
MMP: Matrix metalloproteinase  
LYVE-1: Lymphatic vessel endothelial hyaluronate receptor 1  
GBC: Gallbladder cancer  
EMT: Epithelial-mesenchymal transition  
ECD: E-cadherin  
VIM: Vimentin.

References

[1] N. Normanno, A. de Luca, C. Bianco et al., “Epidermal growth factor receptor (EGFR) signaling in cancer,” Gene, vol. 366, no. 1, pp. 2–16, 2006.
[2] G. Carpenter and S. Cohen, “Epidermal growth factor,” The Journal of Biological Chemistry, vol. 265, no. 14, pp. 7709–7712, 1990.
[3] I. Alroy and Y. Yarden, “The ErbB signaling network in embryogenesis and oncocogenesis: signal diversification through combinatorial ligand-receptor interactions,” FEBS Letters, vol. 410, no. 1, pp. 83–86, 1997.
[4] N. E. Hynes and H. A. Lane, “ERBB receptors and cancer: the complexity of targeted inhibitors,” Nature Reviews Cancer, vol. 5, no. 5, pp. 341–354, 2005.
[5] J. Mendelsohn and J. Baselga, “The EGFR receptor family as targets for cancer therapy,” Oncogene, vol. 19, no. 56, pp. 6550–6565, 2000.
[6] A. J. Wong, J. M. Ruppert, S. H. Bigner et al., “Structural alterations of the epidermal growth factor receptor gene in human gliomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 7, pp. 2965–2969, 1992.
[7] Y. Umekita, Y. Ohi, Y. Sagara, and H. Yoshida, “Co-expression of epidermal growth factor receptor and transforming growth factor-α predicts worse prognosis in breast cancer patients,” International Journal of Cancer, vol. 89, no. 6, pp. 484–487, 2000.
[8] D. L. Uhlman, P. Nguyen, J. C. Manivel et al., “Epidermal growth factor receptor and transforming growth factor α expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis,” Clinical Cancer Research, vol. 1, no. 8, pp. 913–920, 1995.
[9] D. E. B. Swinson, G. Cox, and K. J. O’Byrne, “Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer,” The British Journal of Cancer, vol. 91, no. 7, pp. 1301–1307, 2004.
[10] J. R. Grandis, M. F. Melhem, W. E. Gooding et al., “Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival,” Journal of the National Cancer Institute, vol. 90, no. 11, pp. 824–832, 1998.
[11] K. L. Carraway III and L. C. Cantley, “A new acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling,” Cell, vol. 78, no. 1, pp. 5–8, 1994.
[12] P. van der Geer, T. Hunter, and R. A. Lindberg, “Receptor protein-tyrosine kinases and their signal transduction pathways,” Annual Review of Cell Biology, vol. 10, pp. 251–337, 1996.
[13] A. Ulrich, L. Cousens, J. S. Hayflick et al., “Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells,” Nature, vol. 309, no. 5967, pp. 418–425, 1984.
[14] G. Carpenter, L. King Jr., and S. Cohen, “Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro,” Nature, vol. 276, no. 5686, pp. 409–410, 1978.
[15] H. Ushiro and S. Cohen, “Identification of phosphorytrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes,” The Journal of Biological Chemistry, vol. 255, no. 18, pp. 8363–8365, 1980.
[16] L. C. Groenen, E. C. Nice, and A. W. Burgess, “Structure-function relationships for the EGF/TGF-α family of mitogens,” Growth Factors, vol. 11, no. 4, pp. 235–257, 1994.
[17] H. Toyoda, T. Komurasaki, D. Uchida et al., “Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary
hepatocytes," *The Journal of Biological Chemistry*, vol. 270, no. 13, pp. 7495–7500, 1995.

[18] W. S. Chen, C. S. Lazar, M. Poenie, R. Y. Tsien, G. N. Gill, and M. G. Rosenfeld, "Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor," *Nature*, vol. 328, no. 6133, pp. 820–823, 1987.

[19] R. A. Perugini, T. P. McDade, F. J. Vittimberga Jr., and M. P. Callery, "Pancreatic cancer cell proliferation phosphatidylinositol 3-kinase dependent," *Journal of Surgical Research*, vol. 90, no. 1, pp. 39–44, 2000.

[20] K. M. Nicholson and N. G. Anderson, "The protein kinase B/Akt signalling pathway in human malignancy," *Cellular Signalling*, vol. 14, no. 5, pp. 381–395, 2002.

[21] W. Wang, J. L. Abbruzzese, D. B. Evans, L. Larry, K. R. Cleary, and P. J. Chiao, "The nuclear factor-xB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells," *Clinical Cancer Research*, vol. 5, no. 1, pp. 119–127, 1999.

[22] N. Douziech, E. Calvo, J. Laine, and J. Morisset, "Activation of MAP kinases in growth responsive pancreatic cancer cells," *Cellular Signalling*, vol. 11, no. 8, pp. 591–602, 1999.

[23] K. Yokoi, P. H. Thaker, S. Yazici et al., "Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model," *Cancer Research*, vol. 65, no. 9, pp. 3716–3725, 2005.

[24] R. M. Shaheen, S. A. Ahmad, W. Liu et al., "Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors," *The British Journal of Cancer*, vol. 85, no. 4, pp. 584–589, 2001.

[25] L. B. Saltz, N. J. Meropol, P. J. Loehrner Sr., M. N. Needle, J. Kopit, and R. J. Mayer, "Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor," *Journal of Clinical Oncology*, vol. 22, no. 7, pp. 1201–1208, 2004.

[26] D. Cunningham, Y. Humblet, S. Siena et al., "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer," *The New England Journal of Medicine*, vol. 351, no. 4, pp. 337–345, 2004.

[27] K. P. de Jong, R. Seliemla, A. Karrenbeld et al., "Clinical relevance of transforming growth factor β, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors," *Hepatology*, vol. 28, no. 4, pp. 971–979, 1998.

[28] L. Toschi and F. Cappuzzo, "Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors," *Oncologist*, vol. 12, no. 2, pp. 211–220, 2007.

[29] D. Veale, N. Kerr, G. J. Gibson, P. J. Kelly, and A. L. Harris, "The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival," *The British Journal of Cancer*, vol. 68, no. 1, pp. 162–165, 1993.

[30] A. Rajput, A. P. Koterba, J. L. Kreisberg, J. M. Foster, J. K. Willson, and M. G. Brattain, "A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo," *Cancer Research*, vol. 67, no. 2, pp. 665–673, 2007.

[31] M. L. Janmaat and G. Giacone, "The epidermal growth factor receptor pathway and its inhibition as anticancer therapy," *Drugs of Today*, vol. 39, pp. 61–80, 2003.

[32] J. Mendelsohn, "The epidermal growth factor receptor as a target for cancer therapy," *Endocrine-Related Cancer*, vol. 8, no. 1, pp. 3–9, 2001.

[33] R. S. Herbst, "Review of epidermal growth factor receptor biology," *International Journal of Radiation Oncology Biology Physics*, vol. 59, no. 2, pp. 21–26, 2004.

[34] R. S. Herbst, "Review of epidermal growth factor receptor biology," *International Journal of Radiation Oncology Biology Physics*, vol. 59, no. 2, pp. 21–26, 2004.

[35] R. Radinsky, S. Risin, D. Fan et al., "Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells," *Clinical Cancer Research*, vol. 1, no. 1, pp. 19–31, 1995.

[36] C. Barozzi, M. Ravaiolì, A. D’Errico et al., "Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel," *Cancer*, vol. 94, no. 3, pp. 647–657, 2002.

[37] A. W. Hemmings, N. L. Davis, A. Kluftinger et al., "Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67," *Journal of Surgical Oncology*, vol. 51, no. 3, pp. 147–152, 1992.

[38] M. B. Resnick, J. Routhier, T. Konkin, E. Sabo, and V. E. Pricolo, "Epidermal growth factor receptor, c-MET, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study," *Clinical Cancer Research*, vol. 10, no. 9, pp. 3069–3075, 2004.

[39] A. L. Harris, "Hypoxia—a key regulatory factor in tumour growth," *Nature Reviews Cancer*, vol. 2, no. 1, pp. 38–47, 2002.

[40] A. Suhardja and H. Hoffman, "Role of growth factors and their receptors in proliferation of microvascular endothelial cells," *Microscopy Research and Technique*, vol. 60, no. 1, pp. 70–75, 2003.

[41] L. M. Ellis, W. Liu, S. A. Ahmad et al., "Overview of angiogenesis: biologic implicat ions for antiangiogenic therapy," *Seminars in Oncology*, vol. 28, no. 5, supplement 16, pp. 94–104, 2001.

[42] R. R. Langley and I. J. Fidler, "Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis," *Endocrine Reviews*, vol. 28, no. 3, pp. 297–321, 2007.

[43] G. P. Gupta and J. Massagué, "Cancer metastasis: building a framework," *Cell*, vol. 127, no. 4, pp. 679–695, 2006.

[44] I. J. Fidler, S. Yano, R. Zhang, T. Fujimaki, and C. D. Bucana, "The seed and soil hypothesis: vascularisation and brain metastases," *The Lancet Oncology*, vol. 3, no. 1, pp. 53–57, 2002.

[45] B. Hobson and J. Denekamp, "Endothelial proliferation in tumours and normal tissues: continuous labelling studies," *The British Journal of Cancer*, vol. 67, no. 2, pp. 665–673, 2007.

[46] A. Eberhard, S. Kahlert, V. Goede, B. Hemmerlein, K. H. Plate, and H. G. Augustin, "Heterogeneity of angiogenesis and tumour stromal fibroblast interactions in the context of cancer metastasis," *Cancer Research*, vol. 64, no. 11, pp. 3727–3730, 2004.

[47] S. Iqbal and H. Lenz, "Integration of novel agents in the treatment of colorectal cancer," *Cancer Chemistry and Biology*, vol. 9, no. 2, pp. 1388–1393, 2000.

[48] S. J. Kim, H. Uehara, T. Karashima, D. L. Shepherd, J. J. Killion, and I. J. Fidler, "Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice," *Clinical Cancer Research*, vol. 9, no. 3, pp. 1200–1210, 2003.
[50] T. Sasaki, T. Nakamura, R. B. Rebhun et al., "Modification of the primary tumor microenvironment by transforming growth factor α-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model," The American Journal of Pathology, vol. 173, no. 1, pp. 205–216, 2008.

[51] N. Ferrara and T. Davis-Smyth, "The biology of vascular endothelial growth factor," Endocrine Reviews, vol. 18, no. 1, pp. 4–25, 1997.

[52] L. F. Dvorak, M. F. Dvorak, and A. M. Dvorak, "Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis," The American Journal of Pathology, vol. 146, no. 5, pp. 1029–1039, 1995.

[53] O. R. F. Mook, W. M. Frederiks, and C. J. F. van Noorden, "The role of gelatinases in colorectal cancer progression and metastasis," Biochimica et Biophysica Acta, vol. 1705, no. 2, pp. 69–89, 2004.

[54] S. F. Schoppmann, P. Birner, and J. Stöckl et al., "Tumor-associated vascular integrins enhance the functional capacity of human colorectal tumor vessels," The American Journal of Pathology, vol. 161, no. 3, pp. 947–956, 2002.

[55] K. Maruyama, J. Asai, M. Li, T. Thorne, D. W. Losordo, and P. A. D’Amore, "Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing," The American Journal of Pathology, vol. 170, no. 4, pp. 1178–1191, 2007.

[56] T. Sasaki, Y. Kitadai, T. Nakamura et al., "Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice," Neoplasia, vol. 9, no. 12, pp. 1066–1077, 2007.

[57] N. Saito, S. Kameoka, and R. Furukawa, "Gene profile analysis of colorectal cancer cell lines by cDNA microarray," Oncology reports, vol. 17, no. 5, pp. 1061–1065, 2007.

[58] L. A. Lojoto, J. Kleinerman, and G. M. Saidel, "Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation," Cancer Research, vol. 34, no. 5, pp. 997–1004, 1974.

[59] J. Harder, O. Waiz, F. Otto et al., "EGFR and HER2 expression in advanced biliary tract cancer," World Journal of Gastroenterology, vol. 15, no. 36, pp. 4511–4517, 2009.

[60] M. Kaufman, B. Mehrrota, S. Limaye et al., "EGFR expression in gallbladder carcinoma in North America," International Journal of Medical Sciences, vol. 5, no. 5, pp. 285–291, 2008.

[61] F. Leone, G. Cavalloni, Y. Pignochino et al., "Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma," Clinical Cancer Research, vol. 12, no. 6, pp. 1680–1685, 2006.

[62] A. Ooi, S. Suzuki, K. Nakazawa et al., "Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma," Anticancer Research, vol. 29, no. 1, pp. 19–26, 2009.

[63] Y. Pignochino, I. Sarotto, C. Peraldo-Neia et al., "Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas," BMC Cancer, vol. 10, article 361, 2010.

[64] Y. Sanada, S. Osada, Y. Tokuyama et al., "Critical role of c-Met and Ki67 in progress of biliary carcinoma," The American Surgeon, vol. 76, no. 4, pp. 372–379, 2010.

[65] W. S. Moon, H. S. Park, H. Lee et al., "Co-expression of c-2, C-met and betacatenin in cells forming invasive front of gallbladder cancer," Cancer Research and Treatment, vol. 37, no. 3, pp. 171–176, 2005.

[66] K. Matsumoto, K. Date, H. Shimura, and T. Nakamura, "Acquisition of invasive phenotype in gallbladder cancer cells via mutual interaction of stromal fibroblasts and cancer cells as mediated by hepatocyte growth factor," Japanese Journal of Cancer Research, vol. 87, no. 7, pp. 702–710, 1996.

[67] K. Kitamura, K. Kasuya, A. Tsuchida et al., "Immunohistochemical analysis of transforming growth factor beta in gallbladder cancer," Oncology reports, vol. 10, no. 2, pp. 327–332, 2003.

[68] M. Yukawa, T. Fujimori, D. Hirayama et al., "Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis," Human Pathology, vol. 24, no. 1, pp. 37–40, 1993.

[69] H. Y. Chang, M. C. Kao, T. D. Way, C. T. Ho, and E. Fu, "Diosgenin suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition by down-regulation of Mdm2 and vimentin," Journal of Agricultural and Food Chemistry, vol. 59, no. 10, pp. 5357–5363, 2011.

[70] S. Barr, S. Thomson, E. Buck et al., "Bypassing cellular EGFR receptor dependence through epithelial-to-mesenchymal-like transitions," Clinical and Experimental Metastasis, vol. 25, no. 6, pp. 685–693, 2008.

[71] D. J. McConkey, W. Choi, L. Marquis et al., "Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer," Cancer and Metastasis Reviews, vol. 28, no. 3–4, pp. 335–344, 2009.

[72] A. Moustakas and C. H. Heldin, "Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression," Cancer Science, vol. 98, no. 10, pp. 1512–1520, 2007.

[73] M. Y. Lee, C. Y. Chou, M. J. Tang, and M. R. Shen, "Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation," Clinical Cancer Research, vol. 14, no. 15, pp. 4743–4750, 2008.

[74] A. Hirata, S. Ogawa, T. Kometani et al., "ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase," Cancer Research, vol. 62, no. 9, pp. 2554–2560, 2002.

[75] F. Ciardiello, R. Bianco, V. Damiano et al., "Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225," Clinical Cancer Research, vol. 5, no. 4, pp. 909–916, 1999.

[76] C. Eriehman and D. J. Sargent, "New treatment options for colorectal cancer," The New England Journal of Medicine, vol. 351, no. 4, pp. 391–392, 2004.

[77] B. Liu, M. Fang, M. Schmidt, Y. Lu, J. Mendelsohn, and Z. Fan, "Induction of apoptosis and activation of the caspase cascade by anti-EGFR receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity," The British Journal of Cancer, vol. 82, no. 12, pp. 1991–1999, 2000.

[78] L. Xu, M. Hausmann, W. Dietmaier et al., "Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines," BMC Cancer, vol. 10, article 302, 2010.

[79] H. Ariyama, B. Qin, E. Baba et al., "Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells," Journal of Cellular Biochemistry, vol. 97, no. 4, pp. 724–734, 2006.